Lucia Osoro

Mrs. Lucia Osoro

Université Libre de Bruxelles, Brussels, Brussels-Capital Region, Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
Lucia OsoroLucia Osoro
Lucia Osoro
MZMaura M. Zylla
Maura M. Zylla
FBFrieder Braunschweig
Frieder Braunschweig
FLFrancisco Leyva
Francisco Leyva
JFJosep Figueras
Josep Figueras
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
The accomplishment of value-based healthcare (VBHC) models could save up to $1 trillion per year for healthcare systems worldwide while improving patients’ wellbeing and experience. Nevertheless, its adoption and development are challenging. This review aims to provide an overview of current literature pertaining to the implementation of VBHC models used in cardiology, with a focus on cardiac electrophysiology. This scoping review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis for Scoping Reviews. The records included in this publication were relevant documents published in PubMed, Mendeley, and ScienceDirect. The search criteria were publications about VBHC in the field of cardiology and electrophysiology published between 2006 and 2023. The implementation of VBHC models in cardiology and electrophysiology is still in its infant stages. There is a clear need to modify the current organizational structure in order to establish cross-functional teams with the patient at the centre of care. The adoption of new reimbursement schemes is crucial to moving this process forward. The implementation of technologies for data analysis and patient management, among others, poses challenges to the change process. New VBHC models have the potential to improve the care process and patient experience while optimizing the costs. The implementation of this model has been insufficient mainly because it requires substantial changes in the existing infrastructures and local organization, the need to track adherence to guidelines, and the evaluation of the quality of life improvement and patient satisfaction, among others.

23 April 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
DMDavide Antonio Mei
Davide Antonio Mei
Jacopo Francesco ImbertiJacopo Francesco Imberti
Jacopo Francesco Imberti
Marco VitoloMarco Vitolo
Marco Vitolo
NBNiccolò Bonini
Niccolò Bonini
ECEdoardo Casali
Edoardo Casali
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
Background: Electrophysiology (EP) procedures, including cardiac implantable electronic devices (CIEDs) and ablations, are widely used to manage arrhythmias and heart failure. These interventions, though effective, require substantial resources, prompting the need for systematic economic evaluations to inform healthcare decision-making. Methods: A systematic review of studies from 2007 to 2024 was conducted in two phases. Phase one assessed trends in economic evaluations of EP procedures, analyzing 129 studies across regions and timeframes. Phase two focused on cost-effectiveness analyses of implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy defibrillators (CRT-Ds), and atrial fibrillation (AF) ablation, examining outcomes like quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs), while identifying factors influencing economic results. Results: EP procedures generally demonstrated favorable cost-effectiveness, particularly in high-income regions. Studies on ICDs and CRT-Ds consistently supported their economic value for patients with arrhythmias or heart failure, while AF ablation showed potential for long-term benefits, particularly when compared to medical therapies. However, results varied by region, reflecting differences in healthcare systems, costs, and patient populations. Conclusions: The review highlights the overall cost-effectiveness of EP procedures in many settings but underscores the need for tailored economic evaluations in low- and middle-income countries. Simplified methodologies and greater attention to regional contexts are recommended to guide resource allocation and policy development globally.

Verified
Journal Article
Open access
PDF file
RARuben Casado Arroyo
Ruben Casado Arroyo
Lucia OsoroLucia Osoro
Lucia Osoro
Background and Objective: Innovation is a key enabler of patient-centered care in cardiology, with new medical devices and digital health technologies offering the potential to improve outcomes and efficiency. However, the evaluation of these innovations poses challenges for clinicians, regulators, and procurement stakeholders, particularly within the complex European healthcare landscape. This review aims to explore the current state of health technology assessment (HTA) for cardiology-related medical devices in Europe, offering a clinical perspective. Material and Methods: Three independent scoping reviews were conducted following the PRISMA-ScR guidelines. Keywords included “innovation”, “health technology assessment”, and “cardiology”. The search was supplemented by the relevant literature on European HTA policies, regulatory directives, and emerging technologies. Results: The review identified three central themes: (1) the evolving role of clinicians in HTA processes, (2) the integration of innovative technologies such as digital tools and artificial intelligence within HTA frameworks, and (3) the considerable variation in HTA practices and policies across EU member states. Conclusions: HTA in Europe is undergoing a transformation, with increasing emphasis on interdisciplinary collaboration and frameworks that support innovation. While the goal of harmonization across the EU remains a work in progress, new regulatory efforts, such as the HTA Regulation (HTAR), offer promising avenues for aligning clinical practice with evidence-based assessment and reimbursement decisions.

3 February 2026 in EP Europace
Verified
Journal Article
Open access
Lucia OsoroLucia Osoro
Lucia Osoro
Elena ArbeloElena Arbelo
Elena Arbelo
NKNikola Kozhuharov
Nikola Kozhuharov
RLRuna Landen
Runa Landen
MMMartin Martinek
Martin Martinek
RARuben Casado Arroyo
Ruben Casado Arroyo
Aims: Procurement of cardiac implantable electronic devices (CIEDs) across the European Union is shaped by diverse healthcare systems, reimbursement mechanisms and levels of clinician involvement. Despite a shared legal framework, limited comparative data are available on how procurement is implemented across countries. Objective: The objectives of this study are to examine CIED procurement strategies in 22 European countries where public tendering is mandatory and to explore how clinical, economic and structural factors influence procurement processes. Methods and results: We conducted 23 structured interviews with cardiologists and one industry expert across 22 European countries. A thematic analysis was used to synthesize procurement models, clinical involvement and reimbursement structures. No formal outcome or cost-effectiveness analysis was performed. Procurement models varied widely, encompassing centralized, decentralized and hybrid systems. Clinician involvement ranged from leading device selection based on clinical criteria to being excluded from decision-making in systems driven primarily by price. Reimbursement pathways also differed, with procedure tariffs for single-chamber pacemakers ranging from €1059 to €14 889. A single region in Finland had implemented a pilot value-based procurement model linking payment to patient outcomes. Conclusion: Cardiac implantable electronic device procurement across Europe is heterogeneous and predominantly cost driven, with limited integration of clinical outcomes or value-based principles. While not designed to evaluate cost-effectiveness directly, this study identifies procurement structures that may support or hinder value-based decision-making. Further research is needed to assess how procurement impacts clinical outcomes, innovation adoption and system sustainability.

10 March 2026 in EP Europace
Verified
Journal Article
Open access
Lucia OsoroLucia Osoro
Lucia Osoro
NKNikola Kozhuharov
Nikola Kozhuharov
RLRuna Landen
Runa Landen
Elena ArbeloElena Arbelo
Elena Arbelo
MMMartin Martinek
Martin Martinek
RARuben Casado Arroyo
Ruben Casado Arroyo
Aims: To examine and compare public procurement systems for electrophysiology (EP) consumables across 21 European countries, focusing on governance level, evaluation methods, clinician involvement, reimbursement variability, access to innovation, and sustainability integration. Methods and results: A qualitative, exploratory design was employed using 22 semi-structured interviews with EP clinicians, procurement specialists, and health system stakeholders across 21 countries. Interview transcripts and summaries were thematically coded by two independent researchers using a structured six-domain framework. Substantial heterogeneity in procurement practices was identified. Hospital-level procurement predominates in 43% of countries, while 33% use regional-level tenders; a minority operate national-level frameworks. Evaluation methods vary, with several countries using price-driven criteria, while others apply mixed or clinically weighted models. Clinician involvement is high or moderate in two-thirds of countries but often informal or lacking governance structure. Reimbursement for EP procedures varies widely in scope and transparency, with bundled and global budget models affecting innovation uptake. Innovation access remains uneven: countries such as Austria, the Netherlands, and France use innovation funds or dedicated pathways, while others rely on centralized approvals or re-tendering. Sustainability criteria are rarely formalized in procurement decisions, despite growing awareness of environmental impact. Conclusion: European procurement systems for EP consumables differ markedly in structure, evaluation practices, and alignment with clinical and innovation priorities. Integrating clinician input, adopting value-based frameworks, and embedding sustainability metrics could enhance procurement outcomes and patient care. Harmonized guidance from EHRA and EU-level stakeholders may support more equitable and innovation-friendly procurement strategies.

21 August 2026 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
Lucia OsoroLucia Osoro
Lucia Osoro
NKNikola Kozhuharov
Nikola Kozhuharov
DMDavide Antonio Mei
Davide Antonio Mei
Elena ArbeloElena Arbelo
Elena Arbelo
DLDeirdre Lane
Deirdre Lane
RARuben Casado Arroyo
Ruben Casado Arroyo
Background: Digital Health Technologies (DHTs) are increasingly embedded within VBHC frameworks to enhance outcomes and efficiency. In CV medicine, and particularly EP, they hold transformative potential through remote monitoring, AI and PROMs. Yet, evidence linking DHTs to measurable value remains fragmented Objective: To systematically assess the role of DHTs as enablers of VBHC in cardiology and EP, identifying demonstrated benefits, evidence gaps and research priorities. Methods: Following PRISMA 2020 (PROSPERO CRD420250650295), PubMed, ScienceDirect and Mendeley were searched (2017–2024) for English-language publications combining “digital health” and “value-based healthcare.” Studies meeting ≥2 criteria, VBHC focus, DHT assessment or value-oriented process analysis, were included. Data were synthesised across nine domains: electronic PROMs, mHealth, telemedicine, big data/AI and LHS. Results: Sixty-two studies and twenty-three policy documents were included. Only 4 (6.5%) were RCTs. Eighteen studies (29%) addressed CV conditions, with EP as a key focus. DHTs demonstrated value via improved adherence, earlier AF detection, HF telemonitoring and PROM integration, though few quantified cost-effectiveness or QALYs. Evidence was heterogeneous and geographically uneven. Conclusions: DHTs are pivotal enablers of value-based CV care, but robust outcome-linked evidence, especially in EP, remains limited. Wearables, telemonitoring and ePROMs illustrate measurable value, while AI-driven prediction and workflow optimisation are emerging frontiers. Future work should emphasise pragmatic trials, economic evaluations and standardised outcome metrics to reward digital value creation.